The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression

Journal of Pathology

Volumn 200, Issue 2, 2003, Pages 183-194

  Hanrahan, Vickie ^a   Currie, Margaret J ^a   Gunningham, Sarah P ^a   Morrin, Helen R ^a   Scott, Prudence A E ^b   Robinson, Bridget A ^b   Fox, Stephen B ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenoma; Angiogenesis; Colon carcinoma; Metastasis; Vascular endothelial growth factor

Indexed keywords

MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER INFILTRATION; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIBONUCLEASE PROTECTION ASSAY; STATISTICAL ANALYSIS; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ADENOMA; AGED; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE EXPRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; LYMPHATIC METASTASIS; LYMPHOKINES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037531794     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1339     Document Type: Article

References (62)

1. Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 82-86.
3. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86: 7311-7315.
4. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-858.
5. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50: 1774-1778.
6. Olofsson B, Jeltsch M, Eriksson U, Alitalo K. Current biology of VEGF-B and VEGF-C. Curr Opin Biotechnol 1999; 10: 528-535.
7. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-191.
8. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
9. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60: 203-212.
10. Okamoto K, Oshika Y, Fukushima Y, et al. Xenografts of human solid tumors frequently express cellular-associated isoform of vascular endothelial growth factor (VEGF) 189. Oncol Rep 1999; 6: 1201-1204.
11. Kondo Y, Arii S, Mori A, Furutani M, Chiba T, Imamura M. Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin Cancer Res 2600; 6: 622-630.
12. Bruns CJ, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000; 89: 488-499.
13. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-3968.
14. Kondo Y, Arii S, Furutani M, et al. Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer 2000; 88: 1820-1827.
15. Kang SM, Maeda K, Onoda N, et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 1997; 74: 502-507.
16. Nakata S, Ito K, Fujimori M, et al. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int J Cancer 1998; 79: 179-186.
17. Tokunaga T, Oshika Y, Abe Y, et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998; 77: 998-1002.
18. Landriscina M, Cassano A, Ratio C, et al. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998; 78: 765-770.
19. Harada Y, Ogata Y, Shirouzu K. Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer. Int J Clin Oncol 2001; 6: 221-228.
20. Baker EA, Bergin FG, Leaper DJ. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 2000; 53: 307-12.
21. Nakasaki T, Wada H, Shigemori C, et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002; 69: 247-254.
22. Maeda K, Nishiguchi Y, Yashiro M, et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 2000; 5: 373-378.
23. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78: 1379-1384.
24. Cascinu S, Del Ferro E, Ligi M, et al. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 2001; 19: 8-12.
25. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000; 36: 48-53.
26. Amaya H, Tanigawa N, Lu C, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 1997; 119: 227-235.
27. Andre T, Kotelevets L, Vaillant JC, et al. VEGF, VEGF-B, VEGF-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000; 86: 174-181.
28. Werther K, Christensen IJ, Brunner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma: the Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 2000; 26: 657-662.
29. Dirix LY, Vermeulen PB, Hubens G, et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996; 7: 843-848.
30. Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K. Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998; 93: 249-252.
31. Broll R, Erdmann H, Duchrow M, et al. Vascular endothelial growth factor (VEGF): a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol 2001; 27: 37-42.
32. Karayiannakis AJ, Syrigos KN, Zbar A, et al. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2002; 131: 548-555.
33. Chin KF, Greenman J, Gardiner E, Kumar H, Topping K, Monson J. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000; 83: 1425-1431.
34. Davies MM, Jonas SK, Kaur S, Allen-Mersh TG. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume. Br J Cancer 2000; 82: 1004-1008.
35. Takeda A, Shimada H, Imaseki H, et al. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep 2000; 7: 333-338.
36. Kumar H, Heer K, Lee PW, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4: 1279-1285.
37. Akagi K, Ikeda Y, Miyazaki M, et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer 2000; 83: 887-891.
38. White JD, Hewett PW, Kosuge D, et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 2002; 62: 1669-1675.
39. Furudoi A, Tanaka S, Haruma K, et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 2002; 62: 157-166.
40. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001; 85: 584-589.
41. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6: 3739-3747.
42. Okamoto K, Oshika Y, Fukushima Y, et al. Inhibition of liver metastasis of colon cancer by in vivo administration of antivascular endothelial growth factor antibody. Oncol Rep 1999; 6: 553-556.
43. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001; 2: 278-289.
44. Scott PA, Gleadle JM, Bicknell R, Harris AL. Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. Int J Cancer 1998; 75: 706-712.
45. Gunningham S, Currie M, Cheng H, et al. VEGF-B expression in human breast cancers is associated with positive lymph node status. J Pathol 2001; 193: 325-332.
46. Gunningham S, Currie M, Cheng H, et al. The short form of the alternatively spliced flt-4 but not its ligand VEGF-C is related to lymph node metastasis in human breast cancers. Clin Cancer Res 2000; 6: 4278-4286.
47. Scott PAE, Smith K, Bicknell R, Harris AL. A reliable external control for ribonuclease protection assays. Nucl Acid Res 1997; 25: 1305-1306.
48. Turley H, Scott PA, Watts VM, Bicknell R, Harris AL, Gatter KC. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 1998; 186: 313-318.
49. Giatromanolaki A, Sivridis E, Brekken R, et al. The angiogenic 'vascular endothelial growth factor/flk-1 (KDR) receptor' pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer 2001; 92: 2569-2577.
50. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000; 82: 1427-1432.
51. Kitadai Y, Amioka T, Haruma K, et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001; 93: 662-666.
52. Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999; 5: 1823-1829.
53. Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 2002; 94: 2855-2861.
54. Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999; 81: 845-850.
55. George ML, Tutton MG, Janssen F, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001; 3: 420-427.
56. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997; 3: 1222-1227.
57. Valtola R, Salven P, Heikkil P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154: 1381-1390.
58. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 11709-11714.
59. Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996; 93: 2576-2581.
60. Grimmond S, Lagercrantz J, Drinkwater C, et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res 1996; 6: 124-131.
61. Brown LF, Guidi AJ, Schnitt SJ, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999; 5: 1041-1056.
62. McCarron S, Edwards S, Evans P, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62: 3369-3372.